Corfu HC
Corfu, 49100, Greece
NCT Number: NCT04463875
To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention, by an observational, prospective real-world study in 113 Greek patients with episodic migraine that were prospectively followed-up for three months. The primary endpoint was the change in monthly migraine days between baseline period (BL)and the third month of treatment (T3).
Looking for future studies?
Notify MeAll sexes
Observational
Corfu, 49100, Greece
To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention.
An observational, prospective real-world study. After a one-month baseline period, Vivinor® was introduced in 113 Greek patients with episodic migraine that were prospectively followed-up for three months. The primary endpoint was the change in monthly migraine days between baseline period (BL)and the third month of treatment (T3). Secondary endpoints included changes in mean intensity of migraine and in days with use of acute migraine medications. Changes in scores of Migraine Disability Assessment questionnaire (MIDAS), Headache Impact Test-6 (HIT-6), Migraine Therapy Assessment questionnaire (MTAQ), MSQ-QOL (Migraine-Specific Quality of life questionnaire), HADS (Hospital Anxiety and Depression Scale) were also evaluated. Those with ≥50% reduction in monthly migraine days during T3 compared to BL were considered Vivinor®-responders.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Supplementation per os
Other names: Vivinor
Time frame: 3 months
Change in monthly migraine days between baseline period (BL) and the third month of treatment (T3)
Time frame: 3 months
Changes in mean intensity of migraine between baseline period (BL) and the third month of treatment (T3)
Time frame: 3 months
Changes in days with use of acute migraine medications between baseline period (BL) and the third month of treatment (T3)
Time frame: 3 months
Changes in scores of Migraine Disability Assessment questionnaire (MIDAS) during T3
Time frame: 3 months
Changes in Headache Impact Test-6 (HIT-6) during T3
Time frame: 3 months
Changes in Migraine Therapy Assessment questionnaire (MTAQ) during T3
Time frame: 3 months
Those with ≥50% reduction in monthly migraine days during T3 compared to BL were considered Vivinor®-responders.
Corfu Headache Clinic
Other
Real World, Open Label Prospective Experience of Supplementation With a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04530110
Brain Diseases, Central Nervous System Diseases
Aurora, Colorado, United States
View Trial DetailsNCT07699549
Brain Diseases, Central Nervous System Diseases
Madrid, Spain
View Trial DetailsNCT07720895
Brain Diseases, Central Nervous System Diseases
Athens, Greece
View Trial DetailsNCT06158737
Brain Diseases, Central Nervous System Diseases
Beijing, Beijing Municipality, China
View Trial Details